Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's what I think. Look at the chart and their selling. They had the price pinned at 0.075----selling every day after hours while there was some support (may have been them propping the price up with a low number of shares). The price started to collapse and they stopped selling. In other words the price got away from them so they have eased the selling pressure. Pure technicals. They could care less about conferences. ACTC presents at nearly every conference. Why do some always think it means good news?
Again, look at the chart. It is as ugly as it gets.
Are you serious? You do understand that patients in this trial are not life threatened. This is not good news. Somebody has screwed-up and Tom did not know about it until a few days ago. Most likely there was a serious problem detected by the data management group. The logic is that if there were simply a reporting delay, Tom would have known and would not have said release would be by today.
Did I say that it means anything or suggest to sell???? I was simply responding to a post that said the chart technically looks great. The chart from a purely technical standpoint is frightening. I have not sold.
Here is the pattern. Virtually identicle to ACTC chart.
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:descending_triangle_
You have to be kidding? The chart right now is very nasty. Text book decending triangle. Lower highs with three bounces off lows. It if breaks the lows, there is nothing but vapors below.
I remember back to the good old Dendreon days when hmmmmm, I think it was P3analyze or something like that, monitored the IHUB board. You would have been out of here 10 posts ago.
Everything but the acknowledgement that they will fund with shares is standard biotech boilerplate 10Q language. Nothing new here and no reason to repeat over and over. We get it. ACTC is a startup.
Well the game begins and will go down fast. Thanks for the info Rocky. I have held ACTC for over two years in two equal accounts. So far only buy and hold (avg $0.16). Trading in and out is stupid but I can not help it. I am holding long term, barring a change in the scientific story, in one account and have decided to start trading the other. So, I can compete with myself using two strategies. I sold out of one account at 0.087 on the run and will stay out for now. Friday gave us a big spinning top candle which means indecision. My guess is that the price will trend down in anticipation of the selling of a boat load of free shares. I will wait until things settle out and we get a base and a good candle formation before buying back. I could miss a run on some news, but that is why I have the other account. I do not know why I like to suffer through early stage biotechs as I did for seven years with Dendreon. I got out before the crash and never looked back. I hated that company for every year that I owned it, but I liked the science. Here I do like Gary so at least I do not have to deal with a Mitch Gold. Babbling now so good luck to all.
Not delayed until 2015. Payments or shares are due each quarter--about $487,000 each quarter. No doubt it will be shares.
The link is not to today's presentation. The presentation is supposed to be posted. I can not find it on the site. Can someone help?
ARTICLE OUT IN LANCET
Here is how the peer review process starts. The following is an actual copy of a request sent to me last year
Dear Dr. XXXXXXXXXXXXX,
We request your assistance in reviewing the manuscript listed below (title, author, abstract are given).
Please log on to our Web peer review database at http://www.XXXXXXXXXXXXXXXXXXXXXXX. Your User Name is XXXX. Your password is XXXXXX. Once you log on, please change your password for security reasons if it is the same as your user name. To do this, click on the "My Contact Info" button on the left-hand blue navigation bar, and change the password in the contact information form.
If you need further assistance, contact the Manuscript Office staff at:
E-mail: XXXXXXXXXXXXXXXX
Phone: XXXXXXXXXXXXXX
Fax: XXXXXXXXXXXXXXXXXX
Thank you for considering our request. A prompt response as to whether you agree or do not agree to do the review would be greatly appreciated. This will allow time for the editor to solicit other reviewers if necessary and to not overly delay the review process. If you cannot do the review, it would be greatly appreciated if you could recommend someone else the editor could contact.
Please confirm your willingness to review as soon as possible by logging on, clicking the assigned manuscript title, and then selecting "Agree to Review." This gives us an electronic confirmation that you will review. We request that the review be completed within 20 working days from the date of this request.
Your next steps will be to access the full manuscript in PDF format and then fill out the review form online. While online, click the INSTRUCTIONS FOR REVIEWERS button for some tips and tricks to ease your work. If you decide to add comments to the PDF as part of your review, please make sure that you leave the Author name blank in the comments window.
We appreciate your efforts and hope you know that by participating in the Web review process our entire scientific community will benefit from seeing research published faster.
If you plan to use an annotated PDF for your review, you must make sure that your name does not appear in the properties of each comment. To do this, open the manuscript PDF and insert a comment. Then, right click on the comment and select “Properties.” Under the “General” tab you will see your name. Delete the name and then close the Properties window. Right click on the comment again and select
You are right and you are wrong. First, I am a scientist and I do 6-8 peer reviews for various (nonmedical) journals each year. The guidelines for the peer review process vary and depend on the policy of the journal. Some journals give you up to 6 weeks to complete and return your review. You must agree to the the time limit before being given access to the article. However, some high end journals have special expedited reviews for important breaking research. Here, you might be given as little as 2 weeks to submit your review. The overall time from submission to publication to appearance varies in a big way and is not necessarily correlated to the quality of the journal. Some high end journals might take 1.5 years, whereas some decent but lesser journal might hit the online edition in 4 months. Keep in mind that we are in the middle of a transformation in the publication process with the growing influence of completely electronic journals such as PLOSONE.
So, with respect to ACTC. The only way that I can read Rabin's statement is that it has been submitted, accepted, and is scheduled for publication. If they had merely completed the paper, he has made a completely speculative BS misleading statement.
I would not bother with checking NEJM. Hopefully, it will be Nature. Lanza has a history with Nature. Here is a fact. Any author who publishes a paper in NEJM would give their first born if the same paper was instead accepted by Nature.
If good news is released, the recent volume will be a blip on the chart. You could see over 4 billion shares trade over three days. I recall when Dendreon released the approval news that the volume over two days was 2-3 times outstanding shares. By the way, I got out of Dendreon last year because it is perhaps the sleaziest (how do you spell that)company I have ever encounted. The definition of management greed. I simply could not continue owning it. As it turned out, I got out at a good time. I have felt cleaner ever since and I do not even think about it even for a trade. Here and ADXS is where the money is parked. I think Lanza and Rabin really care about patients. Sure the money will be nice, but Lanza in particular is not in this field for the sole purpose of getting rich.
I am so glad someone has the ability to predict the future. If I had sold today, the news would be out tomorrow and I would be screwed. That is my prediction for myself.
Any posts on todays meeting? I have not been able to keep up today.
Agreed. Rabin has spilled the beans. The treatment worked and it worked in a big way. His comments were as definitive as it is possible to be without damaging the publication process. I am at peace.
One more try. Read your posts and pretend that someone else wrote them. Do you see that you are just flipping coins and guessing? You may get lucky on a couple of trades, but you will get whip sawed based on maybe this or maybe that strategies. To be clear, I do not have my retirement money in this stock. I do have 50% of my trading account and I am willing to lose a great amount of it. The risk I am taking is based on the science and that will be the determining factor for any trade, not guessing what the herd will do tomorrow if Rabin does not say anything new, which I doubt he will. So, if it tanks tomorrow---it was a nice run. I will wait for data.
If you were comfortable buying below ten cents, why are you not comfortable today? Do you believe in this company or not? I will stay all in until the story changes and that would mean that the company has lied to me or the science does not work or both.
Good advice. Unless you are a penney flipping day trader, you own this stock because you think the science works. Although tough on the nerves, being out is a huge risk.
So, assuming the company is sitting on great news what, if any, is the best strategy for releasing the news? Before, during, or after the share dump?
Could the delay be all about the settlements? Most are focusing on a change in protocol, me too, to explain the long delay in the treatment schedule. But, could it be that the delay is all about the lawsuits. I am not a business person. Could anyone suggest a good reason why it would be necessary or advantageous to delay the trials until all shares are dispersed? Would there be a reason why more lawsuits would be filed if the price rose before the persons owed shares receive them?
Greeting: First post here, but lurking for some time. ACTC is my current top investment with non-retirement money. I have been buying since last spring. This will be an eventful year. Hello Fordwill
Bat hotty: Here is what will happen. You will hear that trials are discontinued due to lack of enrollment. You will then hear of redesigned trials. They will all be Provenge + xxxxxxxxxxxxx.
Hi-checking this out